Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent as documented by signature;~2. Documented HIV-1 infection;~3. Enrolled in the Swiss HIV Cohorte Study (SHCS) or receiving care from a medical doctor of the SHCS network;~4. ≥ 18 years of age;~5. HIV-RNA \<50 copies/mL at screening and for at least 24 weeks before screening on effective suppressive cART, one blip with less than 200 copies/mL being allowed during this period if followed by at least 2 results \< 50 copies/mL.~6. On standard cART at the time of inclusion, i.e.:~   * 2 NRTIs + either 1 NNRTI, 1 boosted PI or 1 INSTI;~  * NRTI-sparing triple ARV regimen (e.g. 1 NRTI + 1 NNRTI + 1 InSTI);~  * Dual therapy with protease inhibitor.~Exclusion Criteria:~1. HIV-2 infection;~2. Previous ART change for unsatisfactory virological response, i.e. slow initial virological suppression, incomplete suppression or rebound. Change of drug or drug class for convenience or toxic effect prevention or management is allowed.~   Note: patients with documented genotype(s) presenting only a M184V mutation remain eligible;~3. Creatinine clearance \< 50ml/min;~4. ASAT or ALAT \>2.5x upper limit of the norm;~5. Known hypersensitivity, intolerance or allergy to DTG or FTC;~6. Known or suspected non-adherence (defined as \<80% adherence, i.e. missed doses \> 1x/week) to current treatment in the last 6 months;~7. Concomitant use of drugs that decrease DTG blood concentrations including carbamazepine, oxcarbamazepine, phenytoin, phenobarbital, St John's wort and rifampicin;~8. Women who are pregnant or breast-feeding;~9. a. Presence of any INSTI-resistance. Non-availability of INSTI resistance testing is NOT an exclusion criteria.~   b. Non availability of previous routine resistance test, at least for reverse transcriptase and protease genes.~   Note: Subjects remain eligible in the absence of any previous resistance test only if they are on their first-line antiretroviral regimen;~10. Evidence of acute or chronic hepatitis B virus infection based on results of serology testing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuing cART + Standard monitoring (Type: NO_INTERVENTION): Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
- Continuing cART + Patient-centered monitoring (Type: EXPERIMENTAL): Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
- Switch to DTG+FTC + Standard monitoring (Type: EXPERIMENTAL): Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
- Switch to DTG+FTC + Patient-centered monitoring (Type: EXPERIMENTAL): Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete